Cellosaurus logo
expasy logo

Cellosaurus LNCaP (CVCL_0395)

[Text version]
Cell line name LNCaP
Synonyms LNCAP; LNCap; Ln-Cap; Lymph Node Carcinoma of the prostate
Accession CVCL_0395
Resource Identification Initiative To cite this cell line use: LNCaP (RRID:CVCL_0395)
Comments Group: Space-flown cell line (cellonaut).
Part of: ENCODE project common cell types; tier 3.
Population: Caucasian.
Doubling time: ~60 hours (DSMZ=ACC-256).
Microsatellite instability: Instable (MSI) (PubMed=23671654).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep phosphoproteome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Glycoproteome analysis by proteomics.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
Omics: Virome analysis using proteomics.
Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
Sequence variations
  • Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=22213130).
  • Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from child cell line LNCaP clone FGC).
  • Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from child cell line LNCaP clone FGC).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (PubMed=9090379).
  • Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=14518029).
HLA typing Source: PubMed=26589293
Class I
Class II
Disease Prostate carcinoma (NCIt: C4863)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_M126 (LNCaP 104-S)CVCL_M129 (LNCaP C-33)CVCL_4783 (LNCaP C4)
CVCL_M132 (LNCaP C5)CVCL_1379 (LNCaP clone FGC)CVCL_M133 (LNCaP M)
CVCL_4793 (LNCaP-abl)CVCL_3872 (LNCaP-CL1)CVCL_8986 (LNCaP-CR)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line
STR profile Source(s): CCRID=1101HUM-PUMC000040; CLS=300265; DSMZ=ACC-256; PubMed=11416159; PubMed=14518029; PubMed=25877200

AmelogeninX (CLS=300265)
X,Y (CCRID=1101HUM-PUMC000040; DSMZ=ACC-256; PubMed=11416159; PubMed=14518029; PubMed=25877200)
D2S133816 (DSMZ=ACC-256)
16,17 (CCRID=1101HUM-PUMC000040)
D5S81811,12 (CCRID=1101HUM-PUMC000040; CLS=300265; DSMZ=ACC-256; PubMed=14518029)
11,12,13 (PubMed=25877200)
D7S8208.1,9.1,10.3 (CCRID=1101HUM-PUMC000040; PubMed=25877200)
9,11 (PubMed=14518029)
9.1,10.3 (CLS=300265; DSMZ=ACC-256)
D8S117912,13,14 (DSMZ=ACC-256; PubMed=11416159)
12,14 (CCRID=1101HUM-PUMC000040; CLS=300265; PubMed=14518029; PubMed=25877200)
D13S31710,11,12,13 (PubMed=14518029)
10,12 (CCRID=1101HUM-PUMC000040; CLS=300265; DSMZ=ACC-256; PubMed=25877200)
D18S519,11,12 (CCRID=1101HUM-PUMC000040)
11,12 (CLS=300265; DSMZ=ACC-256; PubMed=14518029; PubMed=25877200)
D19S43313.2,15 (CCRID=1101HUM-PUMC000040)
14,15 (DSMZ=ACC-256)
D21S1128,29,31.2 (PubMed=25877200)
29,31.2 (CLS=300265)
29,31.2,32.2 (DSMZ=ACC-256; PubMed=11416159)
29,32.2 (CCRID=1101HUM-PUMC000040; PubMed=14518029)
FGA19,20 (CCRID=1101HUM-PUMC000040; CLS=300265; PubMed=14518029; PubMed=25877200)
19,20,21 (DSMZ=ACC-256; PubMed=11416159)
Penta D12,12.4
Penta E12,16 (CLS=300265; DSMZ=ACC-256)
16 (PubMed=25877200)

Run an STR similarity search on this cell line
Web pages http://www.lncap.com/

Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman L.Z., Friedman M., Papsidero L.D., Kim U., Chai L.S., Kakati S., Arya S.K., Sandberg A.A.
The LNCaP cell line -- a new model for studies on human prostatic carcinoma.
(In) Models for prostate cancer; Murphy G.P. (eds.); pp.115-132; Alan R. Liss; New York (1980)

Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P.
LNCaP model of human prostatic carcinoma.
Cancer Res. 43:1809-1818(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=2734981; DOI=10.1007/BF00262025
Konig J.J., Kamst E., Hagemeijer A., Romijn J.C., Horoszewicz J.S., Schroder F.H.
Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP.
Urol. Res. 17:79-86(1989)

Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J.
The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth.
Anticancer Res. 16:815-820(1996)

PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H
Webber M.M., Bello D., Quader S.T.A.
Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines.
Prostate 30:58-64(1997)

PubMed=9090379; DOI=10.1038/ng0497-356
Steck P.A., Pershouse M.A., Jasser S.A., Yung W.-K.A., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H.-F., Tavtigian S.V.
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat. Genet. 15:356-362(1997)

PubMed=9460501; DOI=10.1016/s0165-4608(97)00060-5
Nupponen N.N., Hyytinen E.R., Kallioniemi A.H., Visakorpi T.
Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization.
Cancer Genet. Cytogenet. 101:53-57(1998)

PubMed=10702678; DOI=10.1159/000015432
Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N.N., Isola J.J., Visakorpi T., Bergerheim U.S.R., Larsson C.
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.
Cytogenet. Cell Genet. 87:225-232(1999)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000)

PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E
Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.
IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines.
Genes Chromosomes Cancer 30:143-160(2001)

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3
Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.
The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.
Cancer Genet. Cytogenet. 124:112-121(2001)

PubMed=11304728; DOI=10.1002/pros.1045
van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.
Widely used prostate carcinoma cell lines share common origins.
Prostate 47:36-51(2001)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=12606952; DOI=10.1038/sj.onc.1206247
Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I., Crossland S., Stratton M.R., Wooster R., Campbell C., Cooper C.S.
Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays.
Oncogene 22:1247-1252(2003)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands

PubMed=15162376; DOI=10.1002/pros.20031
Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M., Vessella R.L., Belldegrun A.S., Hood L.E.
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.
Prostate 60:98-108(2004)

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=22213130; DOI=10.1002/pros.22480
Spans L., Atak Z.K., Van Nieuwerburgh F., Deforce D., Lerut E., Aerts S., Claessens F.
Variations in the exome of the LNCaP prostate cancer cell line.
Prostate 72:1317-1327(2012)

PubMed=22278370; DOI=10.1074/mcp.M111.014050
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=24587179; DOI=10.1371/journal.pone.0090002
Spans L., Helsen C., Clinckemalie L., Van den Broeck T., Prekovic S., Joniau S., Lerut E., Claessens F.
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.
PLoS ONE 9:E90002-E90002(2014)

PubMed=24618588; DOI=10.1371/journal.pone.0091433
Chernobrovkin A.L., Zubarev R.A.
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.
PLoS ONE 9:E91433-E91433(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26256267; DOI=10.1074/mcp.M115.047928
Shah P., Wang X.-C., Yang W.-M., Toghi Eshghi S., Sun S.-S., Hoti N., Chen L.-J., Yang S., Pasay J., Rubin A., Zhang H.
Integrated proteomic and glycoproteomic analyses of prostate cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.
Mol. Cell. Proteomics 14:2753-2763(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27036029; DOI=10.18632/oncotarget.8456
Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H., Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z., Vander Griend D.J.
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Oncotarget 7:26259-26274(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=29233929; DOI=10.1158/0008-5472.CAN-17-1924
Horning A.M., Wang Y., Lin C.-K., Louie A.D., Jadhav R.R., Hung C.-N., Wang C.-M., Lin C.-L., Kirma N.B., Liss M.A., Kumar A.P., Sun L.-Z., Liu Z.-J., Chao W.-T., Wang Q.-B., Jin V.X., Chen C.-L., Huang T.H.-M.
Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell cycle-related transcription and attenuated androgen response.
Cancer Res. 78:853-864(2018)

PubMed=29660373; DOI=10.1016/j.bbagen.2018.04.012
Touat-Hamici Z., Bulteau A.-L., Bianga J., Jean-Jacques H., Szpunar J., Lobinski R., Chavatte L.
Selenium-regulated hierarchy of human selenoproteome in cancerous and immortalized cells lines.
Biochim. Biophys. Acta 1862:2493-2505(2018)

PubMed=29739788; DOI=10.1158/1078-0432.CCR-18-0410
de Leeuw R., McNair C., Schiewer M.J., Poudel-Neupane N., Brand L.J., Augello M.A., Li Z., Cheng L.C., Yoshida A., Courtney S.M., Hazard E.S., Hardiman G., Hussain M.H., Diehl J.A., Drake J.M., Kelly W.K., Knudsen K.E.
MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.
Clin. Cancer Res. 24:4201-4214(2018)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132
Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.A.
Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.
Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=35502546; DOI=10.1158/0008-5472.CAN-22-1065
Abate-Shen C., Nunes de Almeida F.
Establishment of the LNCaP cell line -- the dawn of an era for prostate cancer research.
Cancer Res. 82:1689-1691(2022)

Cell line collections (Providers) CCTCC; GDC0283
CLS; 300265
Cell line databases/resources CLO; CLO_0007365
CLO; CLO_0037116
MCCL; MCC:0000290
CLDB; cl3243
cancercelllines; CVCL_0395
CCRID; 1101HUM-PUMC000040
DSMZCellDive; ACC-256
Lonza; 109
TOKU-E; 3599
Anatomy/cell type resources BTO; BTO:0001321
Biological sample resources BioSample; SAMN03472386
CRISP screens repositories BioGRID_ORCS_Cell_line; 182
Chemistry resources ChEMBL-Cells; CHEMBL3307965
ChEMBL-Targets; CHEMBL612518
PharmacoDB; LNCAP_850_2019
PubChem_Cell_line; CVCL_0395
Encyclopedic resources Wikidata; Q6459234
Experimental variables resources EFO; EFO_0002071
Gene expression databases ArrayExpress; E-MTAB-2706
GEO; GSE99795
GEO; GSM91927
GEO; GSM142457
GEO; GSM142458
GEO; GSM383948
GEO; GSM383953
GEO; GSM482669
GEO; GSM525800
GEO; GSM784790
GEO; GSM816637
GEO; GSM816634
GEO; GSM844579
GEO; GSM945240
GEO; GSM945282
GEO; GSM1022672
GEO; GSM1029460
GEO; GSM1029461
GEO; GSM1029462
GEO; GSM1029463
GEO; GSM1029464
GEO; GSM1029465
GEO; GSM1029466
GEO; GSM1029467
GEO; GSM1374622
GEO; GSM1374626
GEO; GSM2069518
GEO; GSM2069519
GEO; GSM2069520
GEO; GSM2069521
GEO; GSM2069522
GEO; GSM2069523
GEO; GSM2069524
GEO; GSM2069525
GEO; GSM2650017
GEO; GSM2650018
GEO; GSM2650019
GEO; GSM2650020
GEO; GSM2650021
GEO; GSM2650022
GEO; GSM3145720
Polymorphism and mutation databases Cosmic; 704848
Cosmic; 721368
Cosmic; 721555
Cosmic; 755298
Cosmic; 759895
Cosmic; 801348
Cosmic; 850413
Cosmic; 850745
Cosmic; 850821
Cosmic; 869155
Cosmic; 918500
Cosmic; 920967
Cosmic; 921047
Cosmic; 922553
Cosmic; 923955
Cosmic; 943176
Cosmic; 948076
Cosmic; 949248
Cosmic; 1028648
Cosmic; 1028701
Cosmic; 1066237
Cosmic; 1070886
Cosmic; 1071481
Cosmic; 1071906
Cosmic; 1075275
Cosmic; 1172626
Cosmic; 1176618
Cosmic; 1330909
Cosmic; 1556120
Cosmic; 1689708
Cosmic; 1995486
Cosmic; 2537792
Cosmic; 2580128
Cosmic; 2585151
Cosmic; 2585228
Cosmic; 2621168
Cosmic; 2651770
Cosmic; 2669169
Cosmic; 2816221
IARC_TP53; 21076
Progenetix; CVCL_0395
Proteomic databases PRIDE; PXD000953
PRIDE; PXD000985
PRIDE; PXD002107
PRIDE; PXD002395
PRIDE; PXD003105
PRIDE; PXD003262
PRIDE; PXD006561
PRIDE; PXD032264
Sequence databases EGA; EGAS00001000610
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number42